The ischemia trial: Implication for cardiac imaging in 2020 and beyond

Leipsic JA, Achenbach S (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Radiology: Cardiothoracic Imaging Radiological Society of North America

Book Volume: 2

Article Number: e200021

Journal Issue: 2

DOI: 10.1148/ryct.2020200021

Abstract

Establishing a diagnosis of coronary artery disease (CAD) is more difficult than it would seem. Diagnosis of CAD can be approached in two ways: Detection of ischemia (often with stress myocardial perfusion at SPECT, PET, and cardiac MRI) and visualization of the coronary artery anatomy to demonstrate stenosis (noninvasively with cardiac CT). In addition to providing further supportive evidence for the use of coronary CT angiography as the first-line test for the evaluation of CAD, the ISCHEMIA trial also resulted in some interesting findings with regard to imaging; these findings resulted in the open-ended question of “What does this mean for imagers?”.

Authors with CRIS profile

Stephan Achenbach Lehrstuhl für Innere Medizin II

Involved external institutions

University of British Columbia CA Canada (CA)

How to cite

APA:

Leipsic, J.A., & Achenbach, S. (2020). The ischemia trial: Implication for cardiac imaging in 2020 and beyond. Radiology: Cardiothoracic Imaging, 2(2). https://doi.org/10.1148/ryct.2020200021

MLA:

Leipsic, Jonathon A., and Stephan Achenbach. "The ischemia trial: Implication for cardiac imaging in 2020 and beyond." Radiology: Cardiothoracic Imaging 2.2 (2020).

BibTeX: Download